Inhibitory effects of resistant starch (RS3) as a carrier for stachyose on dextran sulfate sodium‑induced ulcerative colitis in C57BL/6 mice

Qian,Yu; Zhao,Xin; Song,Jia-Le; Zhu,Kai; Sun,Peng; Li,Gui-Jie; Wang,Rui; Kan,Jian-Quan

doi:10.3892/etm.2013.1280

Inhibitory effects of resistant starch (RS3) as a carrier for stachyose on dextran sulfate sodium‑induced ulcerative colitis in C57BL/6 mice

Authors:
- Yu Qian
- Xin Zhao
- Jia-Le Song
- Kai Zhu
- Peng Sun
- Gui-Jie Li
- Rui Wang
- Jian-Quan Kan
View Affiliations

Affiliations: College of Food Science, Southwest University, Chongqing 400715, P.R. China, Department of Biological and Chemical Engineering, Chongqing University of Education, Na'an, Chongqing 400067, P.R. China, Department of Food Science and Nutrition, Pusan National University, Busan 609-735, Republic of Korea
Published online on: September 2, 2013 https://doi.org/10.3892/etm.2013.1280
Pages: 1312-1316

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to determine the effects of resistant starch 3 (RS3) as a carrier for stachyose on dextran sulfate sodium (DSS)‑induced colitis in C57BL/6 mice. RS3 microspheres carrying stachyose (RS3 + stachyose) were produced and evaluated as a potentially improved colitis therapy for this study. The body weights of the mice treated with RS3 + stachyose were higher compared with those of DSS-treated control mice. RS3 + stachyose reduced the levels of the serum pro-inflammatory cytokines IL-6 and TNF-α to a greater extent compared with the same concentration of stachyose combined with ordinary starch (stachyose + starch). Histopathological examination of sections of colon tissues showed that the RS3 + stachyose group recovered well from colitis; however, the tissue sections of the stachyose + starch group presented necrosis to a more serious degree. These results suggest that stachyose with an RS3 carrier has better preventative effects on colitis than stachyose alone in mice.

View Figures

View References

1.	No authors listed:. Report of a Joint FAO/WHO Expert Consultation: Carbohydrates in human nutrition. FAO Food Nutr Pap. 66:1–140. 1998.
2.	Englyst HN, Kingman SM and Cummings JH: Classification and measurement of nutritionally important starch fractions. Eur J Clin Nutr. 46(Suppl 2): S33–S50. 1992.PubMed/NCBI
3.	Baghurst PA, Baghurst KI and Record SJ: Dietary fiber, non-starch polysaccharides and resistant starch - a review. Food Australia. 48(Suppl): S1–S36. 1996.
4.	Yin J, Yang G, Wang S and Chen Y: Purification and determination of stachyose in Chinese artichoke (Stachys Sieboldii Miq.) by high-performance liquid chromatography with evaporative light scattering detection. Talanta. 70:208–212. 2006.PubMed/NCBI
5.	Liying Z, Li D, Qiao S, Johnson EW, Li B, Thacker PA and Han IK: Effects of stachyose on performance, diarrhoea incidence and intestinal bacteria in weanling pigs. Arch Tierernahr. 57:1–10. 2003.PubMed/NCBI
6.	Macfarlane GT and Cummings JH: Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? West J Med. 171:187–191. 1999.
7.	Xu Q, Chao YL and Wan QB: Health benefit application of functional oligosaccharides. Carbohydrate Polymers. 77:435–441. 2009. View Article : Google Scholar
8.	Jian R, Besterman HS, Sarson DL, et al: Colonic inhibition of gastric secretion in man. Dig Dis Sci. 26:195–201. 1981. View Article : Google Scholar : PubMed/NCBI
9.	Seo GS and Choi SC: Pathophysiology of ulcerative colitis - relationship with genetics and immunity. Korea J Med. 76:643–648. 2009.(In Korean).
10.	Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al European Crohn’s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 55(Suppl 1): 1–15. 2006.
11.	Ramadori G and Armbrust T: Cytokines in the liver. Eur J Gastroenterol Hepatol. 13:777–784. 2001. View Article : Google Scholar : PubMed/NCBI
12.	McCurry KR, Campbell DA Jr, Scales WE, Warren JS and Remick DG: Tumor necrosis factor, interleukin 6, and the acute phase response following hepatic ischemia/reperfusion. J Surg Res. 55:49–54. 1993. View Article : Google Scholar : PubMed/NCBI
13.	Ming WJ, Bersani L and Mantovani A: Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 138:1469–1472. 1987.PubMed/NCBI
14.	Fayyaz M and Lackner JM: Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag. 4:41–48. 2008.PubMed/NCBI
15.	Melgar S, Karlsson L, Rehnström E, Karlsson A, Utkovic H, Jansson L and Michaëlsson E: Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int immunopharmacol. 8:836–844. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Ogawa A, Andoh A, Araki Y, Bamba T and Fujiyama Y: Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 110:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Piqué JM and Panés J: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 80:1541–1551. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB and Ruddle FH: Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15–p21. Genomics. 2:203–208. 1988.PubMed/NCBI
19.	van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M and Lowry SF: Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis. 176:439–444. 1997.PubMed/NCBI
20.	Gosselin D and Rivest S: Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr Hyde duality of the innate immune system. Brain Behav Immun. 21:281–289. 2007.PubMed/NCBI
21.	Wan GS, Zhao ZZ, Qian YL, Xie ZH, Wang ZH and Zhu JJ: Changes in serum levels of SOCS-3, IL-6 and TNF-α and their correlation in patients with ulcerative colitis. World Chinese J Digestol. 19:3370–3373. 2011.(In Chinese).
22.	Barondeau DP, Kassmann CJ, Bruns CK, Tainer JA and Getzoff ED: Nickel superoxide dismutase structure and mechanism. Biochemistry. 43:8038–8047. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Gaze DC: The role of existing and novel cardiac biomarkers for cardioprotection. Curr Opin Investig Drugs. 8:711–717. 2007.PubMed/NCBI
24.	Alscher RG, Erturk N and Heath LS: Role of superoxide dismutases (SODs) in controlling oxidative stress in plants. J Exp Bot. 53:1331–1341. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Topping DL and Clifton PM: Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 81:1031–1064. 2001.PubMed/NCBI
26.	Berggren AM, Bjorck IM, Nyman EM and Eggum BO: Short-chain fatty acid content and pH in caecum of rats given various sources of carbohydrates. J Sci Food Agri. 63:397–406. 1993.